AGL 38.54 Increased By ▲ 0.97 (2.58%)
AIRLINK 129.50 Decreased By ▼ -3.00 (-2.26%)
BOP 5.61 Decreased By ▼ -0.03 (-0.53%)
CNERGY 3.86 Increased By ▲ 0.09 (2.39%)
DCL 8.73 Decreased By ▼ -0.14 (-1.58%)
DFML 41.76 Increased By ▲ 0.76 (1.85%)
DGKC 88.30 Decreased By ▼ -1.86 (-2.06%)
FCCL 35.00 Decreased By ▼ -0.08 (-0.23%)
FFBL 67.35 Increased By ▲ 0.85 (1.28%)
FFL 10.61 Increased By ▲ 0.46 (4.53%)
HUBC 108.76 Increased By ▲ 2.36 (2.22%)
HUMNL 14.66 Increased By ▲ 1.26 (9.4%)
KEL 4.75 Decreased By ▼ -0.11 (-2.26%)
KOSM 6.95 Increased By ▲ 0.10 (1.46%)
MLCF 41.65 Decreased By ▼ -0.15 (-0.36%)
NBP 59.60 Increased By ▲ 1.02 (1.74%)
OGDC 183.00 Increased By ▲ 1.75 (0.97%)
PAEL 26.25 Increased By ▲ 0.55 (2.14%)
PIBTL 5.97 Increased By ▲ 0.14 (2.4%)
PPL 146.70 Decreased By ▼ -1.70 (-1.15%)
PRL 23.61 Increased By ▲ 0.39 (1.68%)
PTC 16.56 Increased By ▲ 1.32 (8.66%)
SEARL 68.30 Decreased By ▼ -0.49 (-0.71%)
TELE 7.23 Decreased By ▼ -0.01 (-0.14%)
TOMCL 35.95 Decreased By ▼ -0.05 (-0.14%)
TPLP 7.85 Increased By ▲ 0.45 (6.08%)
TREET 14.20 Decreased By ▼ -0.04 (-0.28%)
TRG 50.45 Decreased By ▼ -0.40 (-0.79%)
UNITY 26.75 Increased By ▲ 0.35 (1.33%)
WTL 1.21 No Change ▼ 0.00 (0%)
BR100 9,806 Increased By 37.8 (0.39%)
BR30 29,678 Increased By 278.1 (0.95%)
KSE100 92,304 Increased By 366.3 (0.4%)
KSE30 28,840 Increased By 96.6 (0.34%)
Markets

Oil tumbles 4pc as new virus strain revives demand fears

  • Brent climbed above $50 last week for the first time since March, buoyed by optimism stemming from COVID-19 vaccines.
Published December 22, 2020

NEW YORK: Oil prices tumbled about 4pc on Monday as a fast-spreading new coronavirus strain that has shut down much of Britain and led to tighter restrictions in Europe sparked worries about a slower recovery in fuel demand.

Brent crude was down $2.10, or 4pc, at $50.16 a barrel by 12:36 p.m. EST (1736 GMT), while U.S. West Texas Intermediate (WTI) crude for delivery in January fell $1.97, or 4pc, to $47.13 ahead of expiry.

The more active February WTI contract fell $2, or 4.1pc, to $47.24 a barrel.

Both contracts had lost as much as $3 earlier in the session, their biggest daily drop in six months.

The strength in the U.S. dollar also weighed on oil markets. A strong greenback makes dollar-denominated commodities like crude oil more expensive to holders of other currencies.

"Reports of a new strain of the coronavirus have weighed on risk sentiment and oil. New mobility restrictions across Europe are also not helping as European oil demand will suffer," said UBS oil analyst Giovanni Staunovo.

"Investors need to be mindful that the road to higher oil demand and prices will remain bumpy."

Brent climbed above $50 last week for the first time since March, buoyed by optimism stemming from COVID-19 vaccines.

But a new COVID-19 strain, said to be up to 70pc more transmissible than the original, has renewed fears about the virus, which has killed about 1.7 million people worldwide.

More countries closed their borders to Britain on Monday, causing travel chaos and raising the prospect of UK food shortages.

"The new strain of the coronavirus in the UK has shown us that the vaccine optimism holding Brent above $50 per barrel could be deflated in a fleeting moment," said Rystad Energy analyst Louise Dickson.

The new virus strain has already been detected in other countries, including Australia, the Netherlands and Italy.

Russian Deputy Prime Minister Alexander Novak said the new strain had an impact on oil prices, adding that recovery of global oil markets was happening more slowly than previously expected and could take two to three years.

"Travel restrictions over the next several weeks will complicate OPEC+ plans to gradually raise output," said Edward Moya, senior market analyst at OANDA in New York.

"The monthly meetings will be very tense and keep oil prices volatile until the virus spread is under control across both Europe and the U.S."

The negative sentiment overshadowed the rollout of a new vaccine in the United States, a deal among U.S. congressional leaders for a $900 billion coronavirus aid package and European regulatory approval on Monday for the use of the COVID-19 vaccine jointly developed by U.S. company Pfizer Inc and its German partner BioNTech.

The approval by Europe's medicines regulator puts the region on course to start inoculations within a week.

Comments

Comments are closed.